Skip to content

Feasibility Study of a Protocol to Treat Pediatric Oral Mucositis by Low-level Laser Therapy

Feasibility Study of a Treatment Protocol of Pediatric Chemo- and Radiotherapy-induced Oral Mucositis by Low-level Laser Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02604329
Acronym
PEDIALASE
Enrollment
22
Registered
2015-11-13
Start date
2015-12-31
Completion date
2017-02-14
Last updated
2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Mucositis

Keywords

low level laser therapy, oral mucositis, child

Brief summary

Low Level Laser Therapy has been used for a few years in some pediatric hospital centers for chemo- and radiotherapy-induced oral mucositis care. It may promote ulceration's healing, limits mucositis severity and associated pain. As its use is recommended in the treatment of radio induced mucositis in adults, the level of evidence in pediatric studies does not allow a precise treatment protocol. The investigators present here the protocol of a feasibility study in the haemato-oncology department of the Children University Hospital of Toulouse, with the view to a future efficacy study.

Detailed description

This study aims to evaluate the feasibility of using low level laser therapy (LLLT) in the haemato-oncology department of the Children University Hospital of Toulouse. The feasibility will be considered as acceptable if 60% of patients hospitalized for oral mucositis had successfully benefit from the procedure. The secondary objectives are the evaluation of efficacy of LLLT on pain and mucositis grade, the evaluation of tolerance of this treatment and the medical time needed for this supportive care. The athermic phototherapy laser diode will be used by scanning the entire oral mucosa area. It will be applied uniformly every two days as long as grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).

Interventions

DEVICEOncolase Digi therapy laser diode

The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm). * Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW). * Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm.

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Hospitalization in the oncology ward of the university hospital Toulouse France * Onco-haematological paediatric patients treated by radio- and /or chemo-therapy, affected by an oral mucositis of WHO grade 2 to 4, * lack of any physical or psychological disease which could interfere with the realization of the study.

Exclusion criteria

* Onco-haematological paediatric patients treated by radio- and /or chemo-therapy, affected by an oral mucositis of WHO's grade under 2 * Child suffering from epilepsy * Patient wearing a cardiac pacemaker * Patient not able to open their mouth at least 20 mm * Patient refusing the wearing of safety goggles.

Design outcomes

Primary

MeasureTime frameDescription
Success of the procedure for each included child7 daysThe procedure is successful when low level laser has been used on all the oral mucosa minimum 3 times in the first 7 days of mucositis of grade 2. The failure of the procedure is therefore declared if the laser was applied within 3 times within 7 days.
Participation rate1 yearNumber of included patients related to the number of patients hospitalized for mucositis with a WHO grade of 2 or more, in one year.

Secondary

MeasureTime frameDescription
Evaluation of mucositis grade7 daysThe World Health Organization (WHO) mucositis grade, before and after each laser application
Efficacy of low level laser therapy in the treatment of oral mucositis of grade 27 daysEfficacy of low level laser therapy will be evaluate by medical caregivers with VAS (Visual Analogic Scale), before and after each laser application
Evaluation of the number of laser treatment sessions7 daysEvaluation of the number of laser treatment sessions related to the mucositis episode
Evaluation of medical time needed for the treatment7 daysEvaluation of the time spent with the patients for the treatment of oral mucositis by the medical staff
Pain evaluation with the Venham scale7 daysBy medical caregiver delivering the laser treatment with the Venham scale modified by Veerkamp and OPS (Objective Pain Scale) for children under 6.
Pain evaluation with the HEDEN mucositis pain scale7 daysPain evaluation by medical caregivers with the HEDEN mucositis pain scale (Hétero Evaluation Douleur Enfant)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026